BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 32299813)

  • 1. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
    Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
    Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity.
    Moosavi SH; Eide PW; Eilertsen IA; Brunsell TH; Berg KCG; Røsok BI; Brudvik KW; Bjørnbeth BA; Guren MG; Nesbakken A; Lothe RA; Sveen A
    Genome Med; 2021 Sep; 13(1):143. PubMed ID: 34470666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
    Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
    J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection.
    Sveen A; Løes IM; Alagaratnam S; Nilsen G; Høland M; Lingjærde OC; Sorbye H; Berg KC; Horn A; Angelsen JH; Knappskog S; Lønning PE; Lothe RA
    PLoS Genet; 2016 Jul; 12(7):e1006225. PubMed ID: 27472274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
    Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.
    Cioce M; Fumagalli MR; Donzelli S; Goeman F; Canu V; Rutigliano D; Orlandi G; Sacconi A; Pulito C; Palcau AC; Fanciulli M; Morrone A; Diodoro MG; Caricato M; Crescenzi A; Verri M; Fazio VM; Zapperi S; Levrero M; Strano S; Grazi GL; La Porta C; Blandino G
    J Exp Clin Cancer Res; 2023 Jul; 42(1):170. PubMed ID: 37460938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer.
    Graziano F; Ruzzo A; Giacomini E; Ricciardi T; Aprile G; Loupakis F; Lorenzini P; Ongaro E; Zoratto F; Catalano V; Sarti D; Rulli E; Cremolini C; De Nictolis M; De Maglio G; Falcone A; Fiorentini G; Magnani M
    Pharmacogenomics J; 2017 Jun; 17(3):258-264. PubMed ID: 26927284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KHDRBS3 promotes multi-drug resistance and anchorage-independent growth in colorectal cancer.
    Ukai S; Sakamoto N; Taniyama D; Harada K; Honma R; Maruyama R; Naka K; Hinoi T; Takakura Y; Shimizu W; Ohdan H; Yasui W
    Cancer Sci; 2021 Mar; 112(3):1196-1208. PubMed ID: 33423358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.
    Tiriac H; Belleau P; Engle DD; Plenker D; Deschênes A; Somerville TDD; Froeling FEM; Burkhart RA; Denroche RE; Jang GH; Miyabayashi K; Young CM; Patel H; Ma M; LaComb JF; Palmaira RLD; Javed AA; Huynh JC; Johnson M; Arora K; Robine N; Shah M; Sanghvi R; Goetz AB; Lowder CY; Martello L; Driehuis E; LeComte N; Askan G; Iacobuzio-Donahue CA; Clevers H; Wood LD; Hruban RH; Thompson E; Aguirre AJ; Wolpin BM; Sasson A; Kim J; Wu M; Bucobo JC; Allen P; Sejpal DV; Nealon W; Sullivan JD; Winter JM; Gimotty PA; Grem JL; DiMaio DJ; Buscaglia JM; Grandgenett PM; Brody JR; Hollingsworth MA; O'Kane GM; Notta F; Kim E; Crawford JM; Devoe C; Ocean A; Wolfgang CL; Yu KH; Li E; Vakoc CR; Hubert B; Fischer SE; Wilson JM; Moffitt R; Knox J; Krasnitz A; Gallinger S; Tuveson DA
    Cancer Discov; 2018 Sep; 8(9):1112-1129. PubMed ID: 29853643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity.
    Brown KM; Xue A; Julovi SM; Gill AJ; Pavlakis N; Samra JS; Smith RC; Hugh TJ
    J Surg Res; 2018 Jul; 227():158-167. PubMed ID: 29804848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
    Das S; Allen A; Berlin J
    Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases.
    Kryeziu K; Moosavi SH; Bergsland CH; Guren MG; Eide PW; Totland MZ; Lassen K; Abildgaard A; Nesbakken A; Sveen A; Lothe RA
    J Transl Med; 2021 Sep; 19(1):384. PubMed ID: 34496878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.
    Lu M; Zessin AS; Glover W; Hsu DS
    PLoS One; 2017; 12(1):e0169439. PubMed ID: 28060954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy.
    Lee JK; Liu Z; Sa JK; Shin S; Wang J; Bordyuh M; Cho HJ; Elliott O; Chu T; Choi SW; Rosenbloom DIS; Lee IH; Shin YJ; Kang HJ; Kim D; Kim SY; Sim MH; Kim J; Lee T; Seo YJ; Shin H; Lee M; Kim SH; Kwon YJ; Oh JW; Song M; Kim M; Kong DS; Choi JW; Seol HJ; Lee JI; Kim ST; Park JO; Kim KM; Song SY; Lee JW; Kim HC; Lee JE; Choi MG; Seo SW; Shim YM; Zo JI; Jeong BC; Yoon Y; Ryu GH; Kim NKD; Bae JS; Park WY; Lee J; Verhaak RGW; Iavarone A; Lee J; Rabadan R; Nam DH
    Nat Genet; 2018 Oct; 50(10):1399-1411. PubMed ID: 30262818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.